VEGFA Recombinant Proteins and Neutralizing Antibody Tools

Vascular Endothelial Growth Factor A (VEGFA) is a central regulator of angiogenesis and exists in multiple isoforms generated through alternative splicing. VEGFA interacts primarily with VEGFR1 and VEGFR2, with VEGFR2 functioning as a major signaling receptor for endothelial-cell proliferation, migration, survival, and vascular permeability. Hypoxia strongly induces VEGFA expression through HIF-dependent mechanisms, promoting new-vessel formation to restore tissue oxygenation. Persistent VEGFA elevation in tumors, however, contributes to abnormal vasculature, increased permeability, and changes in the immune microenvironment. The VEGFA-VEGFR pathway is therefore a major research axis in tumor angiogenesis, ocular neovascularization, ischemic biology, and cardiovascular disease and is also frequently incorporated into multispecific and immune-vascular therapeutic strategies.

DIMA BIOTECH provides recombinant human VEGFA protein for VEGFA-VEGFR1/2 interaction studies, ELISA, SPR/BLI, immunization, and affinity characterization. A flow cytometry-validated chimeric monoclonal antibody and multiple biosimilar reference antibodies, including biotinylated formats, support VEGFA detection, candidate neutralizing-antibody comparison, capture assays, and method development. DIMA also maintains VEGFA B-cell seed-library and lead-antibody resources that can support downstream humanization, affinity maturation, and in vitro functional assessment.